[go: up one dir, main page]

ATE465150T1 - Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate - Google Patents

Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate

Info

Publication number
ATE465150T1
ATE465150T1 AT07765616T AT07765616T ATE465150T1 AT E465150 T1 ATE465150 T1 AT E465150T1 AT 07765616 T AT07765616 T AT 07765616T AT 07765616 T AT07765616 T AT 07765616T AT E465150 T1 ATE465150 T1 AT E465150T1
Authority
AT
Austria
Prior art keywords
treatment
diseases mediated
derivatives suitable
gpr38 receptor
piperazinyl derivatives
Prior art date
Application number
AT07765616T
Other languages
English (en)
Inventor
Darren Mitchell
Jonathan Seal
Mervyn Thompson
Susan Westaway
Samantha Brown
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38476358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE465150(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0612844A external-priority patent/GB0612844D0/en
Priority claimed from GB0711525A external-priority patent/GB0711525D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE465150T1 publication Critical patent/ATE465150T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT07765616T 2006-06-28 2007-06-26 Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate ATE465150T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612844A GB0612844D0 (en) 2006-06-28 2006-06-28 Compounds
GB0711525A GB0711525D0 (en) 2007-06-14 2007-06-14 Compounds
PCT/EP2007/056342 WO2008000729A1 (en) 2006-06-28 2007-06-26 Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases

Publications (1)

Publication Number Publication Date
ATE465150T1 true ATE465150T1 (de) 2010-05-15

Family

ID=38476358

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07765616T ATE465150T1 (de) 2006-06-28 2007-06-26 Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate

Country Status (30)

Country Link
US (2) US7700599B2 (de)
EP (1) EP2041093B1 (de)
JP (1) JP5028484B2 (de)
KR (1) KR20090031688A (de)
AR (1) AR061656A1 (de)
AT (1) ATE465150T1 (de)
AU (1) AU2007263712B2 (de)
BR (1) BRPI0713443A2 (de)
CA (1) CA2655540A1 (de)
CR (1) CR10497A (de)
CY (1) CY1110190T1 (de)
DE (1) DE602007006019D1 (de)
DK (1) DK2041093T3 (de)
EA (1) EA015820B1 (de)
ES (1) ES2344484T3 (de)
HK (1) HK1127608A1 (de)
HR (1) HRP20100284T1 (de)
IL (1) IL195900A0 (de)
JO (1) JO2645B1 (de)
MA (1) MA30539B1 (de)
MX (1) MX2009000110A (de)
MY (1) MY147677A (de)
NO (1) NO20090266L (de)
NZ (1) NZ573450A (de)
PE (1) PE20080345A1 (de)
PL (1) PL2041093T3 (de)
PT (1) PT2041093E (de)
SI (1) SI2041093T1 (de)
TW (1) TWI391386B (de)
WO (1) WO2008000729A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
SI1907374T1 (sl) * 2005-07-26 2012-11-30 Glaxo Group Ltd Derivati benzilpiperazina uporabni za zdravljenje gastrointestinalnih motenj
GB0524814D0 (en) 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
EP2041093B1 (de) * 2006-06-28 2010-04-21 Glaxo Group Limited Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate
GB0723317D0 (en) * 2007-11-28 2008-01-09 Glaxo Group Ltd Compounds
ES2547415T3 (es) * 2009-02-27 2015-10-06 Raqualia Pharma Inc Derivados de oxiindol con actividad agonista del receptor de motilina
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
NZ609596A (en) * 2010-09-27 2013-12-20 Daiichi Sankyo Co Ltd Cyclohexane derivative compound
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
MX377836B (es) 2016-03-17 2025-03-11 F Hoffmann La Roche Ag Derivado de 5-etil-4-metil-pirazol-3-carboxamida teniendo actividad como agonista de receptor asociado con aminas trazas (taar).
EP4219479A4 (de) * 2020-09-25 2024-12-25 Shanghai Meiyue Biotech Development Co., Ltd. Pyrimidincarboxamidverbindung und anwendung davon

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
TW355711B (en) 1992-11-04 1999-04-11 Chugai Pharmaceutical Co Ltd Erythromycin derivatives
JPH06211886A (ja) 1992-11-04 1994-08-02 Chugai Pharmaceut Co Ltd エリスロマイシン誘導体
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
JP3901239B2 (ja) 1996-03-13 2007-04-04 大正製薬株式会社 アリールアルカン誘導体
US5965578A (en) 1996-04-03 1999-10-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19644195A1 (de) 1996-10-24 1998-04-30 Solvay Pharm Gmbh 10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1998023629A1 (fr) 1996-11-26 1998-06-04 Chugai Seiyaku Kabushiki Kaisha Composes de macrolides comportant une chaine a 13 elements, medicament les contenant et leur procede de preparation
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
US5972939A (en) 1997-10-28 1999-10-26 Ortho-Mcneil Pharmaceutical, Inc. Cyclopentene derivatives useful as antagonists of the motilin receptor
US6165985A (en) 1998-02-13 2000-12-26 Solvay Pharmaceuticals Gmbh 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
DE19805822B4 (de) 1998-02-13 2009-02-05 Solvay Pharmaceuticals Gmbh 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9804734D0 (en) 1998-03-05 1998-04-29 Pfizer Ltd Compounds
IL144910A0 (en) * 1999-04-15 2002-06-30 Bristol Myers Squibb Co Cyclic compounds and pharmaceutical compositions containing the same
US20020052380A1 (en) 2000-02-18 2002-05-02 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
US20020010184A1 (en) 2000-02-18 2002-01-24 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
US6392040B2 (en) 2000-03-13 2002-05-21 Ortho-Mcneil Pharmaceutical, Inc. Cyclopentene compounds useful as antagonists of the motilin receptor
US6423714B2 (en) 2000-03-13 2002-07-23 Ortho Mcneil-Pharmaceutical, Inc.. Cyclohexene derivatives useful as antagonists of the motilin receptor
WO2001068622A1 (en) 2000-03-13 2001-09-20 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclobutene derivatives useful as antagonists of the motilin receptor
US6511980B2 (en) * 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1392679B1 (de) 2001-05-10 2005-11-02 Solvay Pharmaceuticals GmbH Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
GB0129013D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US7262195B2 (en) 2003-09-17 2007-08-28 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
US7338954B2 (en) 2003-09-17 2008-03-04 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
EP1667958A2 (de) * 2003-10-01 2006-06-14 The Procter & Gamble Company Antagonisten des melaninkonzentrierenden hormons
WO2005063720A1 (ja) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
EP1744751A4 (de) 2004-03-18 2010-03-10 Brigham & Womens Hospital Verfahren zur behandlung von synucleinopathien
US20070293539A1 (en) 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
SE0401345D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
JP2009501199A (ja) 2005-07-12 2009-01-15 グラクソ グループ リミテッド Ｇｐｒ３８アゴニストとしてのピペラジンヘテロアリール誘導体
SI1907374T1 (sl) * 2005-07-26 2012-11-30 Glaxo Group Ltd Derivati benzilpiperazina uporabni za zdravljenje gastrointestinalnih motenj
EP2041093B1 (de) * 2006-06-28 2010-04-21 Glaxo Group Limited Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate

Also Published As

Publication number Publication date
BRPI0713443A2 (pt) 2012-03-06
JP5028484B2 (ja) 2012-09-19
KR20090031688A (ko) 2009-03-27
US7700599B2 (en) 2010-04-20
HK1127608A1 (en) 2009-10-02
DK2041093T3 (da) 2010-08-02
JO2645B1 (en) 2012-06-17
EP2041093B1 (de) 2010-04-21
AR061656A1 (es) 2008-09-10
US20080027065A1 (en) 2008-01-31
AU2007263712B2 (en) 2012-08-30
SI2041093T1 (sl) 2010-07-30
CA2655540A1 (en) 2008-01-03
MA30539B1 (fr) 2009-06-01
MX2009000110A (es) 2009-01-23
AU2007263712A1 (en) 2008-01-03
EA015820B1 (ru) 2011-12-30
PT2041093E (pt) 2010-06-28
ES2344484T3 (es) 2010-08-27
EP2041093A1 (de) 2009-04-01
JP2009541432A (ja) 2009-11-26
PE20080345A1 (es) 2008-05-29
US8853218B2 (en) 2014-10-07
HRP20100284T1 (hr) 2010-06-30
CY1110190T1 (el) 2015-01-14
NZ573450A (en) 2011-11-25
EA200970065A1 (ru) 2009-06-30
PL2041093T3 (pl) 2010-09-30
US20090192160A1 (en) 2009-07-30
TW200817352A (en) 2008-04-16
NO20090266L (no) 2009-03-17
CR10497A (es) 2009-03-20
MY147677A (en) 2012-12-31
TWI391386B (zh) 2013-04-01
WO2008000729A1 (en) 2008-01-03
IL195900A0 (en) 2009-09-01
DE602007006019D1 (de) 2010-06-02

Similar Documents

Publication Publication Date Title
ATE465150T1 (de) Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate
FR20C1014I2 (fr) Traitement de troubles du cycle sommeil-eveil
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005015562D1 (de) Verwendung eines nmda-rezeptor-antagonisten für die behandlung von durch cochleäre exzitotoxizität hervorgerufenem tinnitus
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
EP2176283A4 (de) Verfahren und zusammensetzungen zur behandlung von hirnerkrankungen
ATE478864T1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
EP3871639C0 (de) Vorrichtung zur behandlung von gastroösophagealer refluxkrankheit
EP2034839A4 (de) Behandlung neurodegenerativer krankheiten durch hemmung von hsp90
EP2259679A4 (de) Verfahren für die behandlung von kallikreinbedingten störungen
EP2034844A4 (de) Verfahren für die behandlung von reizdarm-syndrom des diarrhö-typs
EP2063889A4 (de) Spiropiperidin-beta-sekretase-hemmer zur behandlung der alzheimer-krankheit
ATE399155T1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
EP2215048A4 (de) Antagonisten des p2x3-rezeptors zur behandlung von schmerzen
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
EP2046315A4 (de) Therapeutische mittel zur behandlung maligner lymphome
DK2046762T3 (da) Triazolphenylbenzensulfonamider
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
EP1962869A4 (de) Behandlung von atemwegserkrankungen
EP2217238A4 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit proteinurie
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2041093

Country of ref document: EP